Filing Flows

Filing Flows › 8-K events › Artiva Biotherapeutics

Artiva Biotherapeutics: costs of exit or disposal activities

Form 8-K/A filed Nov 9, 2026 · items 2.05

What the filing says

On October 27, 2026, Artiva Biotherapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) disclosing that the Company’s board of directors approved the discontinuation of the Company’s development of AlloNK ® (AB-101), its non-genet

Read the filing on SEC EDGAR →

What usually followsAcross 955 8-Ks reporting Item 2.05 (exit or disposal costs) in our universe, the stock's median move the next session was −0.2% (typical size ±2.4%, up 47% of the time); over the following 21 sessions, +0.5%. Every item ranked →

What this kind of filing means

Item 2.05 — Costs of exit or disposal activities. Exit and restructuring costs: the charges to expect, the cash part, and the jobs or sites affected.

Other recent restructuring

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.